1)Hruban RH, Goggins M, Parsons J, et al : Progression model for pancreatic cancer. Clin Cancer Res 6:2969-2972,2000
2)Chari ST, Leibson CL, Rabe KG, et al : Pancreatic cancer-associated diabetes mellitus : prevalence and temporal association with diagnosis of cancer. Gastroenterology 134:95-101,2008
3)Tanaka M, Fernández-del Castillo C, Adsay V, et al : International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology 12:183-197,2012
4)Haba S, Yamao K, Bhatia V, et al : Diagnostic ability and factors affecting accuracy of endoscopic ultrasound-guided fine needle aspiration for pancreatic solid lesions : Japanese large single center experience. J Gastroenterol 48:973-981,2013
5)Yang R, Lu M, Qian X, et al : Diagnostic accuracy of EUS and CT of vascular invasion in pancreatic cancer : a systematic review. J Cancer Res Clin Oncol 140:2077-2086,2014
6)Heinemann V, Haas M, Boeck S : Neoadjuvant treatment of borderline resectable and non-resectable pancreatic cancer. Ann Oncol 24:2484-2492,2013
7)Fukutomi A, Uesaka K, Boku N et al : JASPAC 01 : Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 for patients with resected pancreatic cancer. J Clin Oncol 31(suppl):4008,2013
8)Ueno H, Ioka T, Ikeda M, et al : Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan : GEST study. J Clin Oncol 31:1640-1648,2013
9)Conroy T, Desseigne F, Ychou M, et al : FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364:1817-1825,2011
10)Von Hoff DD, Ervin T, Arena FP, et al : Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369:1691-1703,2013
11)Oettle H, Post S, Neuhaus P, et al : Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer : a randomized controlled trial. JAMA 297:267-277,2007